Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lineage Cell Therapeutics's revenue for the
three
months ended in Mar. 2026 was $1.73 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $14.78 Mil.
Lineage Cell Therapeutics's Revenue per Share for the
three
months ended in Mar. 2026 was $0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06.
Warning Sign:
Lineage Cell Therapeutics Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Lineage Cell Therapeutics was 37.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 49.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Lineage Cell Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 118.30% per year. The lowest was -51.60% per year. And the median was -6.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (LCTX) has a Revenue of $14.78 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Lineage Cell Therapeutics and its competitors.
Is Lineage Cell Therapeutics' Revenue too high?
Lineage Cell Therapeutics' current Revenue is $14.78 Mil. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Revenue compare to NWBO and ABEO?
Lineage Cell Therapeutics' Revenue of $14.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Lineage Cell Therapeutics and its competitors. Lineage Cell Therapeutics's current Revenue is $14.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.32, compared to a current price of $1.19 — trading 10.2% below its estimated fair value. The current Revenue is $14.78 Mil. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Revenue is $14.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.19 is trading 10.2% below its estimated GF Value™ of $1.32.
GuruFocus considers Lineage Cell Therapeutics to be Modestly Undervalued.
Key valuation signals for LCTX:
Revenue: $14.78 Mil
GF Value™: $1.32 vs. price of $1.19 (10.2% below fair value)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for LCTX
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
